X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET

Company Participants

Glenn Schulman - Vice President, Investor Relations and Corporate Communications

Paula Ragan - President and Chief Executive Officer

Adam Mostafa - Chief Financial Officer

Diego Cadavid - Chief Medical Officer

Arthur Taveras - Chief Scientific Officer

Conference Call Participants

Marc Frahm - Cowen & Company

William Wood - B. Riley Securities

Trevor Howard - Oppenheimer

Zegbeh Jallah - ROTH Capital Partners

Operator

Greetings and welcome to X4 Pharmaceuticals First Quarter 2022 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference call is being recorded.

It is now my pleasure to introduce your host Dr. Glenn Schulman, Head of Investor Relations. Please begin.

Glenn Schulman

Thank you, operator and good morning everyone. Presenting on today's call will be X4's Chief Executive Officer, Dr. Paula Ragan and the company's Chief Financial Officer, Adam Mostafa. Following prepared remarks by each, we will open the call to your questions, during which we'll also be joined by our Chief Scientific Officer, Art Taveras; Chief Medical Officer, Diego Cadavid; and Chief Operating Officer, Mary DiBiase. As a reminder, on today's call X4 will be making forward-looking statements regarding regulatory and product development plans as well as research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in X4's most recent filings with the SEC.

With that, I'd now like to turn the call over to X4’s President and CEO, Dr. Paula Ragan. Paula?

Paula Ragan

Thanks, Glenn. And thank you everyone for joining us on this call this morning. On this morning's call, I'll provide a brief update on recent accomplishments, highlight a few of our important upcoming catalysts, including the readout from our Phase 3 4WHIM trial, and of course, open up the calls to any questions you may have for the team. As a reminder, our lead candidate mavorixafor, CXCR4 for antagonists, is being evaluated as an oral once daily treatment for people with rare disorders of the immune system, including people diagnosed with WHIM syndrome and chronic neutropenia, and also for those diagnosed with certain lymphoma. WHIM syndrome is a rare immune deficiency disorder caused by genetic mutations to the CXCR4 receptor. The disease is characterized by HPV associated Wart, Hypogammaglobulinemia, multiple types of infections and Myelokathexis.